trending Market Intelligence /marketintelligence/en/news-insights/trending/Jxt52uqrtVk8956anvw-0w2 content esgSubNav
In This List

AbbVie, Principia Biopharma terminate immunology collaboration

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


AbbVie, Principia Biopharma terminate immunology collaboration

AbbVie Inc. and Principia Biopharma Inc. mutually agreed to end a collaboration for the development of potential drugs known as oral immunoproteasome inhibitors.

Under the 2017 agreement, the companies were partnering to conduct research and pre-clinical studies of the potential treatments for autoimmune and inflammatory disorders. AbbVie was meant to initiate clinical development and commercialize the compounds discovered from the partnership.

South San Francisco, Calif.-based Principia has reacquired the rights to the program, with the termination effective in March.